Targeted Gene Delivery Therapies for Cervical Cancer
MetadataShow full item record
Cervical cancerTargeted gene therapyDelivery systemsImmunopotentiationCervical cancer stem cells
Áyen, Á., Jiménez Martínez, Y., & Boulaiz, H. (2020). Targeted Gene Delivery Therapies for Cervical Cancer. Cancers, 12(5), 1301. [doi:10.3390/cancers12051301]
SponsorshipThis research was supported by the Fundación Mutua Madrileña (project FMM-AP16683-2017) and Consejería de Salud Junta de Andalucía (PI-0089-2017).
Despite being largely preventable through early vaccination and screening strategies, cervical cancer is the most common type of gynecological malignancy worldwide and constitutes one of the leading causes of cancer deaths in women. Patients with advanced or recurrent disease have a very poor prognosis; hence, novel therapeutic modalities to improve clinical outcomes in cervical malignancy are needed. In this regard, targeted gene delivery therapy is presented as a promising approach, which leads to the development of multiple strategies focused on different aspects. These range from altered gene restoration, immune system potentiation, and oncolytic virotherapy to the use of nanotechnology and the design of improved and enhanced gene delivery systems, among others. In the present manuscript, we review the current progress made in targeted gene delivery therapy for cervical cancer, the advantages and drawbacks and their clinical application. At present, multiple targeted gene delivery systems have been reported with encouraging preclinical results. However, the translation to humans has not yet shown a significant clinical benefit due principally to the lack of efficient vectors. Real efforts are being made to develop new gene delivery systems, to improve tumor targeting and to minimize toxicity in normal tissues.